Wall Street analysts expect Bausch Health Companies Inc (NYSE:BHC) to post earnings of $1.08 per share for the current fiscal quarter, according to Zacks. Seven analysts have issued estimates for Bausch Health Companies’ earnings, with the highest EPS estimate coming in at $1.34 and the lowest estimate coming in at $0.99. Bausch Health Companies reported earnings of $1.15 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 6.1%. The business is expected to issue its next quarterly earnings results on Tuesday, November 5th.
On average, analysts expect that Bausch Health Companies will report full-year earnings of $4.15 per share for the current year, with EPS estimates ranging from $4.08 to $4.37. For the next fiscal year, analysts anticipate that the business will report earnings of $4.40 per share, with EPS estimates ranging from $3.56 to $4.85. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Bausch Health Companies.
Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.03 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.03). Bausch Health Companies had a positive return on equity of 52.12% and a negative net margin of 10.88%. The business had revenue of $2.15 billion for the quarter, compared to analyst estimates of $2.15 billion. During the same quarter last year, the firm posted $0.93 EPS. The company’s revenue was up 1.1% compared to the same quarter last year.
A number of research analysts have issued reports on BHC shares. TD Securities upgraded Bausch Health Companies from a “hold” rating to a “buy” rating and set a $28.00 price target for the company in a research report on Thursday, August 15th. Guggenheim started coverage on Bausch Health Companies in a research report on Thursday, September 12th. They set a “buy” rating and a $30.00 price target for the company. Wells Fargo & Co reiterated a “sell” rating on shares of Bausch Health Companies in a research report on Tuesday, September 17th. Wolfe Research started coverage on Bausch Health Companies in a research report on Friday, July 19th. They set an “outperform” rating and a $31.00 price target for the company. Finally, Mizuho set a $45.00 price target on Bausch Health Companies and gave the stock a “buy” rating in a research report on Thursday, June 20th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and twelve have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $29.68.
BHC stock traded up $0.13 during trading on Wednesday, reaching $21.83. 105,625 shares of the company’s stock were exchanged, compared to its average volume of 2,841,896. The company has a quick ratio of 0.92, a current ratio of 1.21 and a debt-to-equity ratio of 8.94. Bausch Health Companies has a 1-year low of $17.20 and a 1-year high of $28.45. The company’s fifty day moving average price is $22.06 and its 200-day moving average price is $23.42. The firm has a market cap of $7.64 billion, a PE ratio of 5.43 and a beta of 0.80.
In other news, CEO Joseph C. Papa acquired 30,000 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were bought at an average price of $23.31 per share, with a total value of $699,300.00. Also, insider William D. Humphries acquired 30,703 shares of the company’s stock in a transaction dated Friday, August 16th. The stock was purchased at an average cost of $21.18 per share, for a total transaction of $650,289.54. The disclosure for this purchase can be found here. Insiders sold a total of 18,159 shares of company stock worth $410,355 in the last three months. Company insiders own 11.87% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. FIL Ltd raised its position in shares of Bausch Health Companies by 69.6% during the first quarter. FIL Ltd now owns 10,545,300 shares of the company’s stock worth $260,170,000 after purchasing an additional 4,327,851 shares during the period. Vanguard Group Inc. raised its position in shares of Bausch Health Companies by 4.0% during the second quarter. Vanguard Group Inc. now owns 9,513,863 shares of the company’s stock worth $239,940,000 after purchasing an additional 363,579 shares during the period. Bank of Montreal Can raised its position in Bausch Health Companies by 43.7% during the second quarter. Bank of Montreal Can now owns 5,318,505 shares of the company’s stock valued at $134,133,000 after buying an additional 1,616,428 shares during the period. Renaissance Technologies LLC raised its position in Bausch Health Companies by 9.8% during the second quarter. Renaissance Technologies LLC now owns 3,037,200 shares of the company’s stock valued at $76,598,000 after buying an additional 272,000 shares during the period. Finally, Clearbridge Investments LLC raised its position in Bausch Health Companies by 0.5% during the first quarter. Clearbridge Investments LLC now owns 2,897,282 shares of the company’s stock valued at $71,563,000 after buying an additional 14,610 shares during the period. 56.01% of the stock is currently owned by institutional investors.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Recommended Story: Coverage Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.